Barclays analyst Stephanie Davis maintains $Evolent Health (EVH.US)$ with a buy rating, and adjusts the target price from $39 to $19.
According to TipRanks data, the analyst has a success rate of 45.2% and a total average return of -4.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
Evolent Health's Q3 EBITDA was notably below consensus, primarily due to a considerable rise in Oncology costs, which were experienced both retrospectively and within the quarter. Despite this setback, the company's recent signing of $200M in new run-rate business during Q3 underscores the growing demand for specialty care management.
Evolent Health's third-quarter financial performance was seen as underwhelming. Previous expectations indicated that the company was positioned to recover a significant portion of higher expenses through contractual rate enhancements. Despite this, the market's response implies skepticism regarding the company's capability to reach approximately $300M in EBITDA. Nevertheless, it is considered that the current challenges are atypical, and there is confidence that Evolent's profit margins will stabilize as the negotiated price increments come into play.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Stephanie Davis維持$Evolent Health (EVH.US)$買入評級，並將目標價從39美元下調至19美元。
根據TipRanks數據顯示，該分析師近一年總勝率為45.2%，總平均回報率為-4.6%。
此外，綜合報道，$Evolent Health (EVH.US)$近期主要分析師觀點如下：
evolent health的第三季EBITDA明顯低於共識，主要是由於腫瘤學成本大幅上升，這種增加需要進行審視且在該季度內發生。儘管遇到了這一挫折，但該公司最近在第三季度簽署了20000萬元新的業務，突顯了專科護理管理需求的增長。
evolent health的第三季財務表現被視爲令人失望。之前的預期表明，該公司通過合同費率的提高定位於恢復更大比例的支出。儘管如此，市場的反應暗示了對該公司達到約30000萬元EBITDA的能力的懷疑。然而，目前的挑戰被認爲是非典型的，並且有信心認爲隨着談判價格的遞增，evolent的利潤率將穩定。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
